Acrivon Therapeutics (ACRV) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 0.5% versus a loss of 36.4%. Zhengye Biotechnology is the larger company by market cap ($82.0 million vs $81.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | ZYBT |
|---|---|---|
| Share price | $1.91 | $1.73 |
| Market cap | $81.85M | $81.99M |
| 1-day change | +2.14% | +50.45% |
| YTD return | -22.41% | +50.43% |
| 1-year return | -0.53% | -36.40% |
| EPS (TTM) | $-1.88 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $8.01 |
| 52-week low | $1.27 | $0.616 |
| Distance from 52-week high | -46.35% | -78.40% |
| Analyst consensus | none | — |
| Avg. price target upside | +502.09% | — |
| Average volume | 356.18K | 5.10M |
| Shares outstanding | 42.85M | 47.39M |
| Employees | 74 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed ZYBT by 35.9 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
ACRV vs ZYBT FAQ
Which is bigger, Acrivon Therapeutics or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $81.99M compared with $81.85M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or ZYBT?
ACRV returned -0.53% over the past 12 months, compared with -36.40% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.